New drug HRS-9813 aims to slow lung scarring in fibrosis patients
NCT ID NCT07192939
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 30 times
Summary
This study tests an experimental drug called HRS-9813 in 270 adults with pulmonary fibrosis (IPF or PPF). The goal is to see if it can improve lung function and slow disease progression. Participants are randomly assigned to receive either the drug or a placebo, and neither they nor their doctors will know which they get. The trial is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPF AND PPF are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Academy of Medical Sciences & Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact
Conditions
Explore the condition pages connected to this study.